An Integrative Genomic and Transcriptomic Analysis Reveals Potential Targets Associated with Cell Proliferation in Uterine Leiomyomas

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Da Cirilo, Priscilaniele Ramos ^a,b   Marchi, Fábio Albuquerque ^b,c   de Barros Filho, Mateus Camargo ^b   Rocha, Rafael Malagoli ^b   Domingues, Maria Aparecida Custódio ^a   Jurisica, Igor ^d   Pontes, Anagloria ^a   Rogatto, Silvia Regina ^a,b  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRCA1 PROTEIN; FANCONI ANEMIA GROUP A PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; SOMATOMEDIN BINDING PROTEIN 5; TUMOR MARKER;

ADULT; ARTICLE; CELL PROLIFERATION; COMPARATIVE GENOMIC HYBRIDIZATION; COMPUTER MODEL; DATA ANALYSIS; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENETIC ALGORITHM; GENETIC SCREENING; GENOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; MOLECULAR BIOLOGY; MYOMETRIUM; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; TARGET CELL; TISSUE SECTION; TRANSCRIPTOMICS; TUMOR GENE; UPREGULATION; UTERUS MYOMA;

CELL PROLIFERATION; CLUSTER ANALYSIS; DATABASES, GENETIC; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; GENOMICS; HEPATIC STELLATE CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 5; LEIOMYOMA; MICRORNAS; PROTEIN INTERACTION MAPS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; UTERINE NEOPLASMS;

EID: 84874582462     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057901     Document Type: Article

References (69)

1. Baird DD, Dunson DB, (2003) Why is parity protective for uterine fibroids? Epidemology 14: 247-250.
2. Mantovani MS, Barbieri NJ, Philbert PMP, (1999) Multiple uterine leiomyomas: Cytogenetic analysis. Gynecol Oncol 72: 71-75.
3. Cook H, Ezzati M, Segars JH, McCarthy K, (2010) The impact of uterine leiomyomas on reproductive outcomes. Minerva Ginecol 62: 225-236.
4. Flake GP, Andersen J, Dixon D, (2003) Etiology and pathogenesis of uterine leiomyomas: a review. Environ Health Perspect 111: 1037-1054.
5. Ishikawa H, Ishi K, Serna VA, Kakazu R, Bulun SE, et al. (2010) Progesterone is essential for maintenance and growth of uterine leiomyoma. Endocrinology 151: 2433-2442.
6. Sozen I, Arici A, (2002) Interactions of cytokines, growth factors, and the extracellular matrix in the cellular biology of uterine leiomyomata. Fertil Steril 78: 1-12.
7. Georgieva B, Milev I, Minkov I, Dimitrova I, Bradford AP, et al. (2012) Characterization of the uterine leiomyoma microRNAome by deep sequencing. Genomics 99: 275-281.
8. Bonatz G, Frahm SO, Andreas S, Heidorn K, Jonat W, et al. (1998) Telomere shortening in uterine leiomyomas. Am J Obstet Gynecol 179: 591-596.
9. Malik M, Norian J, McCarthy-Keith D, Britten J, Catherino WH, (2010) Why leiomyomas are called fibroids: the central role of extracellular matrix in symptomatic women. Semin Reprod Med 28: 169-179.
10. Canevari RA, Pontes A, Rogatto SR, (2005) Microallelotyping defines novel regions of loss of heterozygosity in uterine leiomyomas. Mol Carcinog 42: 177-182.
11. Canevari RA, Rogatto SR, (2007) Uterine leiomyoma: updates in cytogenetics and molecular analysis. Asian J Cancer 6: 15-28.
12. El-Gharib MN, Elsobky ES, (2010) Cytogenetic aberrations and the development of uterine leiomyomata. J Obstet Gynaecol Res 36: 101-107.
13. Hodge JC, Kim T, Dreyfuss JM, Somasundaram P, Christacos NC, et al. (2012) Expression profiling of uterine leiomyomata cytogenetic subgroups reveals distinct signatures in matched myometrium: transcriptional profiling of the t(12;14) and evidence in support of predisposing genetic heterogeneity. Hum Mol Genet 21: 2312-2329.
14. Mäkinen N, Mehine M, Tolvanen J, (2011) MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 334: 252-255.
15. Arslan AA, Gold LI, Mittal K, Suen TC, Belitskaya-Levy I, et al. (2005) Gene expression studies provide clues to the pathogenesis of uterine leiomyoma: new evidence and a systematic review. Hum Reprod 20: 852-863.
16. Quade BJ, Wang TY, Sornberger K, Dal Cin P, Mutter GL, et al. (2004) Molecular pathogenesis of uterine smooth muscle tumors from transcriptional profiling. Genes Chrom Cancer 40: 97-108.
17. Vanharanta S, Wortham NC, Laiho P, Sjöberg J, Aittomäki K, et al. (2005) 7q deletion mapping and expression profiling in uterine fibroids. Oncogene 24: 6545-6554.
18. Hodge JC, Park PJ, Dreyfuss JM, Assil-Kishawi I, Somasundaram P, et al. (2009) Identifying the molecular signature of the interstitial deletion 7q subgroup of uterine leiomyomata using a paired analysis. Genes Chrom Cancer 48: 865-885.
19. Akavia UD, Litvin O, Kim J, Sanchez-Garcia F, Kotliar D, et al. (2010) An integrated approach to uncover drivers of cancer. Cell 143: 1005-1017.
20. Staaf J, Jönsson G, Ringnér M, Vallon-Christersson J, Grabau D, et al. (2010) High-resolution genomic and expression analyses of copy number alterations in HER2-amplified breast cancer. Breast Cancer Res 12: R25.
21. Curtis C, Shah SP, Chin SF, Turashvili G, Rueda OM, et al. (2012) The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486: 346-352.
22. Jönsson G, Staaf J, Vallon-Christersson J, Ringnér M, Holm K, et al. (2010) Genomic subtypes of breast cancer identified by array-comparative genomic hybridization display distinct molecular and clinical characteristics. Breast Cancer Res 12: R42.
23. Brown KR, Jurisica I, (2005) Online predicted human interaction database. Bioinformatics 21: 2076-2082.
24. Brown KR, Otasek D, Ali M, McGuffin MJ, Xie W, et al. (2009) NAViGaTOR: Network Analysis, Visualization and Graphing Toronto. Bioinformatics 25: 3327-3329.
25. Gozgit JM, Wong MJ, Moran L, Wardwell S, Mohemmad QK, et al. (2012) Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models. Mol Cancer Ther 11: 690-699.
26. Becker MA, Hou X, Harrington SC, Weroha SJ, Gonzalez SE, et al. (2012) IGFBP ratio confers resistance to IGF targeting and correlates with increased invasion and poor outcome in breast tumors. Clin Cancer Res 18: 1808-1817.
27. Packenham JP, Du Manoir S, Schrock E, Risinger JI, Dixon D, et al. (1997) Analysis of genetic alterations in uterine leiomyomas and leiomyosarcomas by comparative genomic hybridization. Mol Carcinog 19: 273-279.
28. Levy B, Mukherjee T, Hirschhorn K, (2000) Molecular cytogenetic analysis of uterine leiomyomata and leiomyosarcoma by comparative genomic hybridization. Cancer Genet Cytogenet 121: 1-8.
29. Vanharanta S, Wortham NC, Langford C, El-Bahrawy M, Van der Spuy Z, et al. (2007) Definition of a minimal region of deletion of chromosome 7 in uterine leiomyomas by tiling-path microCGH array and mutation analysis of known genes in this region. Genes Chrom Cancer 46: 451-458.
30. Nikitenko LL, Cross T, Campo L, Turley H, Leek R, et al. (2006) Expression of terminally glycosylated calcitonin receptor-like receptor in uterine leiomyoma: endothelial phenotype and association with microvascular density. Clin Cancer Res 12: 5648-5658.
31. Behera MA, Feng L, Yonish B, Catherino W, Jung SH, et al. (2007) Thrombospondin-1 and thrombospondin-2 mRNA and TSP-1 and TSP-2 protein expression in uterine fibroids and correlation to the genes COL1A1 and COL3A1 and to the collagen cross-link hydroxyproline. Reprod Sci 14: 63-76.
32. Anania CA, Stewart EA, Quade BJ, Hill JA, Nowak RA, (1997) Expression of the fibroblast growth factor receptor in women with leiomyomas and abnormal uterine bleeding. Mol Hum Reprod 3: 685-691.
33. Dixon D, He H, Haseman JK, (2000) Immunohistochemical localization of growth factors and their receptors in uterine leiomyomas and matched myometrium. Environ. Health Perspect 5: 795-802.
34. Bussey KJ, Chin K, Lababidi S, Reimers M, Reinhold WC, et al. (2006) Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel. Mol Cancer Ther 5: 853-867.
35. Pascale A, Govoni S, (2012) The complex world of post-transcriptional mechanisms: is their deregulation a common link for diseases? Focus on ELAV-like RNA-binding proteins. Cell Mol Life Sci 69: 501-517.
36. Filipowicz W, Bhattacharyya SN, Sonenberg N, (2008) Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 9: 102-114.
37. Huppi K, Volfovsky N, Mackiewicz M, Runfola T, Jones TL, et al. (2007) MicroRNAs and genomic instability. Semin Cancer Biol 17: 65-73.
38. Lujambio A, Lowe SW, (2012) The microcosmos of cancer. Nature 482: 347-355.
39. Zavadil J, Ye H, Liu Z, Wu J, Lee P, et al. (2010) Profiling and functional analyses of microRNAs and their target gene products in human uterine leiomyomas. PLoS One 5: e12362.
40. Hoeijmakers JHJ, (2001) Genome maintenance mechanisms for preventing cancer. Nature 411: 366-374.
41. Crabtree JS, Jelinsky SA, Harris HA, Choe SE, Cotreau MM, et al. (2009) Comparison of human and rat uterine leiomyomata: identification of a dysregulated mammalian target of rapamycin pathway. Cancer Res 69: 6171-6178.
42. Luo X, Ding L, Xu J, (2005) Gene expression profiling of leiomyoma and myometrial smooth muscle cells in response to transforming growth factor-beta. Endocrinol 146: 1097-1118.
43. Dimitrova IK, Richer JK, Rudolph MC, Spoelstra NS, Reno EM, et al. (2009) Gene expression profiling of multiple leiomyomata uteri and matched normal tissue from a single patient. Fertil Steril 91: 2650-2663.
44. Shah AA, Grainger DA, (1996) Contemporary concepts in managing menorrhagia. Medscape Womens Health 12: 8.
45. Desai SS, Hentz VR, (2011) The treatment of Dupuytren disease. J Hand Surg Am 36: 936-942.
46. Turner N, Grose R, (2010) Fibroblast growth factor signalling: from development to cancer. Nat Rev Cancer 10: 116-129.
47. Haugsten EM, Wiedlocha A, Olsnes S, Wesche J, (2010) Roles of fibroblast growth factor receptors in carcinogenesis. Mol Cancer Res 8: 1439-1452.
48. Courjal F, Cuny M, Simony-Lafontaine J, Louason G, Speiser P, et al. (1997) Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res 57: 4360-4367.
49. Elbauomy ES, Green AR, Lambros MB, Turner NC, Grainge MJ, et al. (2007) FGFR1 amplification in breast carcinomas: a chromogenic in situ hybridisation analysis. Breast Cancer Res 9: R23.
50. Turner N, Pearson A, Sharpe R, Lambros M, Geyer F, et al. (2010) FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer. Cancer Res 70: 2085-2094.
51. Yu L, Saile K, Swartz CD, He H, Zheng X, et al. (2008) Differential expression of receptor tyrosine kinases (RTKs) and IGF-I pathway activation in human uterine leiomyomas. Mol Med 14: 264-275.
52. Keisner SV, Shah SR, (2011) Pazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinoma. Drugs 71: 443-454.
53. Güllü G, Karabulut S, Akkiprik M, (2012) Functional roles and clinical values of insulin-like growth factor binding protein-5 in different types of cancers. Chin J Cancer 31: 266-280.
54. McGuire WL Jr, Jackson JG, Figueroa JA, Shimasaki S, Powell DR, et al. (1992) Regulation of insulin-like growth factor-binding protein (IGFBP) expression by breast cancer cells: use of IGFBP-1 as an inhibitor of insulin-like growth factor action. J Natl Cancer Inst 84: 1336-1341.
55. Adesanya OO, Zhou J, Bondy CA, (1996) Cellular localization and sex steroid regulation of insulin-like growth factor binding protein messenger ribonucleic acids in the primate myometrium. J Clin Endocrinol Metab 81: 2495-2501.
56. Giudice LC, Irwin JC, Dsupin BA, Pannier EM, Jin IH, et al. (1993) Insulin-like growth factor (IGF), IGF binding protein (IGFBP), and IGF receptor gene expression and IGFBP synthesis in human uterine leiomyomata. Hum Reprod 8: 1796-1806.
57. Tsibris JCM, Segars J, Coppola D, Mane S, Wilbanks GD, et al. (2002) Insights from gene arrays on the development and growth regulation of uterine leiomyoma. Fertil Steril 78,114-121.
58. Lin N, Chen S, Pan W, Xu L, Hu K, et al. (2011) NP603, a novel and potent inhibitor of FGFR1 tyrosine kinase, inhibits hepatic stellate cell proliferation and ameliorates hepatic fibrosis in rats. Am J Physiol Cell Physiol 301: 469-477.
59. Collin NB, Wilson JB, Bush T, Thomashevski A, Roberts KJ, et al. (2009) ATR-dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function. Blood 113: 2181-2190.
60. Solyom S, Winqvist R, Nikkilä J, Rapakko K, Hirvikoski P, et al. (2011) Screening for large genomic rearrangements in the FANCA gene reveals extensive deletion in a Finnish breast cancer family. Cancer Lett 28: 113-118.
61. Sanchez-Garcia F, Akavia UD, Mozes E, Pe'er D, (2010) Identification of significant targets in cancer. BMC Bioinfo 11: 189-198.
62. Benjamini Y, Hochberg Y, (1995) Controlling the false discovery rate - a practical and powerful approach to multiple testing. J R Stat Soc Series B Stat Methodol 57: 289-300.
63. Thorvaldsdóttir H, Robinson JT, Mesirov JP (2012) Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform In press.
64. Tusher VG, Tibshirani R, Chu G, (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 98: 5116-5121.
65. Storey JD, Tibshirani R, (2003) Statistical significance for genome-wide studies. Proc Natl Acad Sci USA 100: 9440-9445.
66. Segal E, Shapira M, Regev A, Pe'er D, Botstein D, et al. (2003) Module networks: identifying regulatory modules and their condition-specific regulators from gene expression data. Nat Genetics 34: 166-176.
67. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, et al. (2005) Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102: 15545-15550.
68. Reich M, Liefeld T, Gould J, Lerner J, Tamayo P, et al. (2006) GenePattern 2.0. Nat Genetics 38: 500-501.
69. Rosa FE, Caldeira JR, Felipes J, Bertonha FB, Quevedo FC, et al. (2008) Evaluation of estrogen receptor alpha and beta and progesterone receptor expression and correlation with clinicopathologic factors and proliferative marker Ki-67 in breast cancers. Hum Pathol 39: 720-730.